Teledyne Technologies TDY has outperformed the market over the past 20 years by 6.68% on an annualized basis producing an average annual return of 15.18%. Currently, Teledyne Technologies has a market ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Fair Isaac. If we consider the specifics of each trade, it is accurate to state that 38% of the investors opened trades ...

If you want to stay updated on the latest options trades for PepsiCo, Benzinga Pro gives you real-time options trades alerts.

Abbott's Q4 sales grow 7.2%, missing estimates, but analysts remain upbeat with strong 2025 projections driven by Diabetes ...

According to Benzinga Pro, Zebra Technologies's peer group average for short interest as a percentage of float is 7.75%, which means the company has less short interest than most of its peers. Did you ...

According to Benzinga Pro, Fastenal's peer group average for short interest as a percentage of float is 5.03%, which means the company has less short interest than most of its peers. Did you know that ...

Ivanka Trump on Thursday publicly disavowed any connection to a cryptocurrency meme coin being promoted under her name, issuing a strong warning to consumers against falling prey to fraud.

According to Benzinga Pro, Jefferies Financial Gr's peer group average for short interest as a percentage of float is 3.05%, which means the company has more short interest than most of its peers. Did ...

According to Benzinga Pro, Eagle Materials's peer group average for short interest as a percentage of float is 3.34%, which means the company has less short interest than most of its peers. Did you ...

CMS appeals Medicare Star Rating ruling after a judge sided with UnitedHealth over unfair evaluations, impacting the 2025 plan assessments.

One such smart money buy was a biotech company. Let me be upfront and say that I know nothing about biotechnology. I am not a doctor, I have never played a doctor on television, and I generally avoid ...

FY2025 revenue reached $977 million, up 16%, with $165M net income. Growth fueled by NRT portfolio and global generics expansion.